Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
47 hedge funds and large institutions have $9.77M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 18 closing their positions.
19% less funds holding
Funds holding: 58 → 47 (-11)
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
76% less capital invested
Capital invested by funds: $40.7M → $9.77M (-$31M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFGLC
Johnson Financial Group LLC (Colorado)
Denver,
Colorado
|
+$278K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$262K |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$190K |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$122K |
| 5 |
TPMI
Tilden Park Management I
New York
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.34M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
-$1.23M |
| 3 |
DPCM
Darlington Partners Capital Management
Greenbrae,
California
|
-$1.18M |
| 4 |
Tiger Global Management
New York
|
-$1.09M |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$645K |
DNA.WS Hedge Fund Activity: Q1 2022 in Review
47 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q1 2022, worth a combined $9.77M — down 76% from $40.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of DNA.WS and 7 opened new positions — a net loss of 11 holders — while 12 trimmed existing stakes and 4 added.
The largest buyer was Johnson Financial Group LLC (Colorado), opening a new position worth an estimated $278K. The largest seller was Franklin Resources, exiting entirely with an estimated $1.34M sold.
- 47 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q1 2022, down from 58 in Q4 2021.
- Funds reported $9.77M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q1 2022, down 76% quarter-over-quarter.
- 7 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q1 2022 and 18 closed out, a net change of -11 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q1 2022 was Johnson Financial Group LLC (Colorado), an estimated $278K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q1 2022 was Franklin Resources, an estimated $1.34M sold.
Based on aggregated 13F filings for Q1 2022.